Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment
  1. Outputs

Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis

Academic Article
Publication Date:
2021
Short description:
Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis / Gelibter, S., Pisa, M., Croese, T., Finardi, A., Mandelli, A., Sangalli, F., Colombo, B., Martinelli, V., Comi, G., Filippi, M., Furlan, R.. - In: ANNALS OF NEUROLOGY. - ISSN 0364-5134. - 90:2(2021), pp. 253-265. [10.1002/ana.26154]
abstract:
Objective: In vivo measures of myeloid activity are promising biomarkers in multiple sclerosis. We previously demonstrated that cerebrospinal fluid (CSF) myeloid microvesicles are markers of microglial/macrophage activity and neuroinflammation in multiple sclerosis. Here, we aimed at investigating the diagnostic and prognostic value of myeloid microvesicles in a clinical setting. Methods: Six hundred one patients discharged with a diagnosis of neuroinflammatory, neurodegenerative, or no neurological disease were enrolled. Myeloid microvesicles were measured with flow cytometry as isolectin B4–positive events in fresh CSF. Clinical, demographical, and magnetic resonance imaging (MRI) data were collected at diagnosis (all patients) and during follow-up (n = 176). Results: CSF myeloid microvesicles were elevated in neuroinflammatory patients compared to the neurodegenerative and control groups. In multiple sclerosis, microvesicles were higher in patients with MRI disease activity and their concentration increased along with the number of enhancing lesions (p < 0.0001, Jonckheere–Terpstra test). CSF myeloid microvesicles were also higher in patients with higher disease activity in the month and year preceding diagnosis. Microvesicles excellently discriminated between the relapsing–remitting and control groups (receiver operator characteristic curve, area under the curve = 0.939, p < 0.0001) and between radiologically isolated syndrome and unspecific brain lesions (0.942, p < 0.0001). Furthermore, microvesicles were independent predictors of prognosis for both the relapsing–remitting and progressive groups. Microvesicles independently predicted future disease activity in relapsing–remitting patients (hazard ratio [HR] = 1.967, 95% confidence interval [CI] = 1.147–3.372), correcting for prognostic factors of standard clinical use. In the progressive group, microvesicles were independent predictors of disability accrual (HR = 10.767, 95% CI = 1.335–86.812). Interpretation: Our results confirm that CSF myeloid microvesicles are a clinically meaningful biomarker of neuroinflammation and microglial/macrophage activity in vivo. These findings may support a possible use in clinical practice during diagnostic workup and prognostic assessment. ANN NEUROL 2021.
Iris type:
1.1 Articolo in rivista
List of contributors:
Gelibter, S.; Pisa, M.; Croese, T.; Finardi, A.; Mandelli, A.; Sangalli, F.; Colombo, B.; Martinelli, V.; Comi, G.; Filippi, M.; Furlan, R.
Authors of the University:
FILIPPI MASSIMO
FURLAN ROBERTO
Handle:
https://iris.unisr.it/handle/20.500.11768/118100
Published in:
ANNALS OF NEUROLOGY
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.11.1.0